JP6410795B2 - カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 - Google Patents

カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 Download PDF

Info

Publication number
JP6410795B2
JP6410795B2 JP2016506341A JP2016506341A JP6410795B2 JP 6410795 B2 JP6410795 B2 JP 6410795B2 JP 2016506341 A JP2016506341 A JP 2016506341A JP 2016506341 A JP2016506341 A JP 2016506341A JP 6410795 B2 JP6410795 B2 JP 6410795B2
Authority
JP
Japan
Prior art keywords
cancer
target
cto
tumor
acquired resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016506341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515619A (ja
JP2016515619A5 (enExample
Inventor
ラシダ エイ カルマリ
ラシダ エイ カルマリ
Original Assignee
タクティカル セラピューティクス インコーポレイテッド
タクティカル セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タクティカル セラピューティクス インコーポレイテッド, タクティカル セラピューティクス インコーポレイテッド filed Critical タクティカル セラピューティクス インコーポレイテッド
Publication of JP2016515619A publication Critical patent/JP2016515619A/ja
Publication of JP2016515619A5 publication Critical patent/JP2016515619A5/ja
Application granted granted Critical
Publication of JP6410795B2 publication Critical patent/JP6410795B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016506341A 2013-04-01 2014-03-28 カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 Active JP6410795B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/986,103 US9089570B2 (en) 2010-09-03 2013-04-01 Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US13/986,103 2013-04-01
PCT/US2014/032253 WO2014165412A2 (en) 2013-04-01 2014-03-28 Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate

Publications (3)

Publication Number Publication Date
JP2016515619A JP2016515619A (ja) 2016-05-30
JP2016515619A5 JP2016515619A5 (enExample) 2017-05-18
JP6410795B2 true JP6410795B2 (ja) 2018-10-24

Family

ID=51621074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016506341A Active JP6410795B2 (ja) 2013-04-01 2014-03-28 カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物

Country Status (10)

Country Link
US (1) US9089570B2 (enExample)
EP (1) EP2981169B1 (enExample)
JP (1) JP6410795B2 (enExample)
KR (2) KR20210019116A (enExample)
CN (1) CN105120663B (enExample)
AU (1) AU2014248377B2 (enExample)
CA (1) CA2902144C (enExample)
IL (1) IL241827B (enExample)
WO (1) WO2014165412A2 (enExample)
ZA (1) ZA201506037B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016015095A1 (en) * 2014-07-31 2016-02-04 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
KR102456433B1 (ko) 2016-03-02 2022-10-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN107890467A (zh) * 2017-11-24 2018-04-10 中国医学科学院基础医学研究所 干扰能量代谢的药物在胰腺癌复发中的应用
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate
WO2024208247A1 (zh) * 2023-04-04 2024-10-10 广东银珠医药科技有限公司 羧胺三唑在制备治疗肿瘤骨转移的药物中的用途
WO2024235217A1 (zh) * 2023-05-15 2024-11-21 广东银珠医药科技有限公司 一种抗肺癌联合用药物及其应用
CN119971050A (zh) * 2023-11-10 2025-05-13 广东银珠医药科技有限公司 羧胺三唑与化疗药的组合物及联用治疗实体瘤的用途
WO2025214445A1 (zh) * 2024-04-12 2025-10-16 广东银珠医药科技有限公司 一种三氮唑类化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122782A (en) * 1995-07-21 2003-03-12 Gruppe Constantia Triazole salts and pharmaceutical compositions containing the same and methods for evaluating the susceptibility of a cancer to growth inhibition utilizing the same
US5728707A (en) 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
EP2193135A1 (en) * 2007-08-13 2010-06-09 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CN101669941B (zh) * 2008-09-09 2012-11-07 中国医学科学院基础医学研究所 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
US8377973B2 (en) * 2009-09-04 2013-02-19 Tactical Therapeutics Inc Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations

Also Published As

Publication number Publication date
US9089570B2 (en) 2015-07-28
CA2902144A1 (en) 2014-10-09
EP2981169A2 (en) 2016-02-10
CA2902144C (en) 2021-02-09
AU2014248377B2 (en) 2018-02-01
ZA201506037B (en) 2021-09-29
HK1214921A1 (zh) 2016-08-12
JP2016515619A (ja) 2016-05-30
IL241827B (en) 2019-02-28
EP2981169A4 (en) 2016-09-14
KR20210019116A (ko) 2021-02-19
US20140294806A1 (en) 2014-10-02
CN105120663A (zh) 2015-12-02
KR20160026824A (ko) 2016-03-09
WO2014165412A3 (en) 2015-01-29
CN105120663B (zh) 2017-08-04
AU2014248377A1 (en) 2015-09-03
EP2981169B1 (en) 2021-05-05
WO2014165412A2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
JP6410795B2 (ja) カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物
Remon et al. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Troiani et al. Targeting EGFR in pancreatic cancer treatment
EP2815765A1 (en) Overcoming resistance to ERBB pathway inhibitors
EP2249827A1 (en) Use of picoplatin and cetuximab to treat colorectal cancer
CN103533961A (zh) 以表皮生长因子受体为靶向的治疗癌症的组合方法
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2017200016A1 (ja) Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬
Mosquera et al. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials
JP2019514864A (ja) 肝癌の治療方法
Reck et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study
Rapidis et al. Targeted therapies in head and neck cancer: past, present and future
Xu et al. Epidermal growth factor receptor-targeted therapy in colorectal cancer
Kanat et al. Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations
WO2010132596A1 (en) Use of picoplatin to treat colorectal cancer
Dong et al. Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors
US20160367553A1 (en) Methods and Compositions for Treating Cancers having Acquired Resitance to prior Chemotherapeutic and Targeted Drugs Using Carboxyamidotriazole Orotate
WO2023046305A1 (en) [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer
Wang et al. Polypharmacology in Clinical Applications—Anticancer Polypharmacology
HK1214921B (en) Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
Arslan et al. Emerging drugs in metastatic breast cancer: an update
TW202506115A (zh) 一種藥物組合及其應用
WO2023159066A1 (en) Use of niraparib for the treatment of brain cancer
De Jonge et al. 396 A Phase I, Dose-finding Study of BI 853520, a Potent and Selective Inhibitor of Protein Tyrosine Kinase 2 in Patients with Advanced or Metastatic Solid Tumors
EP4213845A1 (en) New use of inhibitors of the notch signalling pathway

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180517

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180925

R150 Certificate of patent or registration of utility model

Ref document number: 6410795

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250